Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Rajasekaran, Sikhamani ^a   Jeyaseelan, Lakshmanan ^b   Vijila, Sundaraj ^a   Gomathi, Chandrahasan ^a   Raja, Krishnaraj ^a  

^a GOVERNMENT GENERAL HOSPITAL   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Antiretroviral therapy; HIV; Second line treatment; Treatment failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SUBSTITUTION; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFORMATION SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INDIA; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGIC METHODS; FEMALE; GOVERNMENT PROGRAMS; HEMOGLOBINS; HIV INFECTIONS; HUMANS; INDIA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; SEX FACTORS; TREATMENT FAILURE;

EID: 34447304363     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279706.24428.78     Document Type: Article

References (15)

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global summary of the HIV/AIDS epidemic. December 2005. Available at: http://www.unaids.org/Unaids/EN/Resources/epidemiology/epicore.asp. Accessed: 28 December 2005.
2. National AIDS Control Organization. Facts and figures. HIV estimates - 2003. Available at: http://www.nacoonline.org/facts_hivestimates.htm. Accessed: 28 December 2005.
3. Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 2006; 6:53-59.
4. Casado JL, Perez-Elfas MJ, Amela A, Sabido R, Marti-Belda P, Dronda F, et al. Predictors of long term response to protease inhibitor therapy in a cohort of HIV infected patients. AIDS 1998; 12:F131-F135.
5. Zaccrelli M, Barracchini A, De Longis P, Perno CF, Soldani F, Liuzzi G, et al. Factors related to virological failure among HIV positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDs 2002; 16:67-73.
6. Hogg RS, Rhone SA, Yip B, Sherlock C, Conway B, Schechter MT, et al. Antiviral effect of double and triple drug combination amongst HIV infected adults: lessons from the implementation of viral load-driven therapy. AIDS 1998; 12:279-284.
7. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
8. Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, et al. Predictors of treatment failure during highly active antiretroviral therapy (Racing Trial). Eur J Med Res 2002; 7:341-346.
9. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1 Infected adults: a EuroSIDA study. J Infect Dis 2004; 190:148-155.
10. World Health Organization. Scaling up antiretroviral therapy in resource limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva: World Health Organization; 2003.
11. Ramakumar R. Technical Demography. New Delhi: Wiley Eastern United; 1986. pp. 32-34.
12. Burger DM, Hoetelmans PWH, Hugen JW, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir containing triple therapy. Antiviral Ther 1998; 3:215-220.
13. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998; 12:2161-2167.
14. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent anti retroviral therapy. AIDS 1999; 13:1873-1880.
15. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-207.